These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38315285)

  • 41. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
    Wang Y; Tang Q; Li M; Jiang S; Wang X
    Biochem Biophys Res Commun; 2014 Feb; 444(2):199-204. PubMed ID: 24440701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
    Chong X; Chen J; Zheng N; Zhou Z; Hai Y; Chen S; Zhang Y; Yu Q; Yu S; Chen Z; Bao W; Quan M; Chen ZS; Zhan Y; Gao Y
    Mol Cancer; 2022 May; 21(1):118. PubMed ID: 35619132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
    Zhang H; Xia Y; Wang F; Luo M; Yang K; Liang S; An S; Wu S; Yang C; Chen D; Xu M; Cai M; To KKW; Fu L
    Adv Sci (Weinh); 2021 May; 8(10):2003404. PubMed ID: 34026438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer.
    Liu YL; Xiang Z; Zhang BY; Zou YW; Chen GL; Yin L; Shi YL; Xu LL; Bi J; Wang Q
    Aging (Albany NY); 2024 Jun; 16(11):9410-9436. PubMed ID: 38848145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
    Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
    Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8
    Huang MY; Chen YC; Lyu WY; He XY; Ye ZH; Huang CY; He XL; Chen X; Chen X; Zhang B; Kai G; Zhang X; Li T; Huang M; Lu JJ
    Pharmacol Res; 2023 Dec; 198():106988. PubMed ID: 37984507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.
    Yan H; Li Y; Wang X; Qian J; Xu M; Peng J; Huang D
    Front Oncol; 2022; 12():867658. PubMed ID: 35669431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
    Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
    Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
    Jiang W; Ouyang X; Li C; Long Y; Chen W; Ji Z; Shen X; Xiang L; Yang H
    Immunology; 2023 Nov; 170(3):419-438. PubMed ID: 37469254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
    Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
    Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
    Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
    Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
    J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.
    Yang L; Liu S; He W; Xiong Z; Xia L
    BMC Cancer; 2023 Mar; 23(1):221. PubMed ID: 36894899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer.
    Matsumoto T; Okayama H; Nakajima S; Saito K; Nakano H; Endo E; Kase K; Ito M; Yamauchi N; Yamada L; Kanke Y; Onozawa H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Mimura K; Kono K
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
    Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
    Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
    Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.